Hypercalcemia as a side effect of potassium binding agents.

Abstract

Hypercalcemia is a potential adverse effect of calcium-containing ion exchange resins, often used in the treatment and prevention of hyperkalemia in chronic kidney disease (CKD). We describe a series of seven outpatients with moderate CKD (mean glomerular filtration rate estimated with the CKD-EPI formula 41.29 ± 10.83 mL/min/1.73 m(2)), presenting mild hypercalcemia in relation to the treatment with calcium polystyrene sulfonate. Serum calcium increased a mean of 0.91 ± 0.46 mg/dL, with a mean concomitant decrease of serum intact parathormone (iPTH) of 52.24 ± 49.29 ng/dL. After treatment withdrawal or dose reduction, we observed a recovery of serum calcium and iPTH values. Treatment with calcic potassium binders should be included in the differential diagnosis of hypercalcemia in patients with moderate CKD.

• Authors: David Arroyo, Nayara Panizo, Soledad García de Vinuesa, Marian Goicoechea, Ursula Verdalles, José Luño
• Journal: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia (Nefrologia) Vol. 32 Issue 5 Pg. 655-8 ( 2012) ISSN: 1989-2284 [Electronic] Spain
• PMID: 23013952 (Publication Type: Journal Article)

Chemical References

• Chelating Agents
• Polystyrenes
• polystyrene sulfonic acid
• Potassium

Topics

• Aged
• Aged, 80 and over
• Chelating Agents (adverse effects)
• Female
• Humans
• Hypercalcemia (chemically induced)
• Male
• Middle Aged
• Polystyrenes (adverse effects)
• Potassium